Skip to main content
TipRanks
Go Ultimate75% OFF

ADARx Pharmaceuticals (ADRX) Financial Statements

9 Followers

ADARx Pharmaceuticals Financial Overview

ADARx Pharmaceuticals's market cap is currently $1.54B. The company's EPS TTM is $-2.46; its P/E ratio is -5.66; ADARx Pharmaceuticals has not announced its next earnings date. See an overview of income statement, balance sheet, and cash flow financials.

Financial overview
Dec 25
Income Statement
Total Revenue$ 3.45M
Gross Profit$ 3.45M
Operating Income$ -88.36M
EBITDA$ -86.04M
Net Income$ -73.09M
Balance Sheet
Cash & Short-Term Investments$ 480.00M
Total Assets$ 507.65M
Total Debt$ 7.74M
Net Debt$ -58.78M
Total Liabilities$ 709.91M
Stockholders' Equity$ -202.25M
Cash Flow
Free Cash Flow$ 259.35M
Operating Cash Flow$ 262.29M
Investing Cash Flow$ -209.93M
Financing Cash Flow$ 97.00K

Currency in USD

ADARx Pharmaceuticals Earnings and Revenue History

-80M-40M040M-2121 %-2120 %-2119 %-2118 %EarningsProfit Margin2025RevenueEarningsProfit Margin

ADARx Pharmaceuticals Liabilities to Assets

0250M500M750M138 %139 %140 %141 %LiabilitiesLiabilities to Assets2025AssetsLiabilitiesLiabilities to Assets

ADARx Pharmaceuticals Cash Flow

-300M-200M-100M0100M200M300M2025OperatingInvestingFinancing

ADARx Pharmaceuticals Forecast EPS vs Actual EPS

-2-1.7-1.5-1.2-1-0.7-0.5Q3 26EPS EstimateBeatMiss